{
    "2019-08-23": [
        [
            {
                "time": "",
                "original_text": "沃森生物上半年扣非净利同比增长84.86%",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "扣非净利",
                        "同比增长",
                        "84.86%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物(300142.SZ)半年度净利润升16.09%至8493.49万元",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "净利润",
                        "上升",
                        "16.09%",
                        "8493.49万元"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：终止治疗用重组人乳头瘤病毒16型E7融合蛋白疫苗研发 并购重组异常",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "终止",
                        "重组人乳头瘤病毒",
                        "疫苗研发",
                        "并购重组",
                        "异常"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：上半年净利润同比增16.09%",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "净利润",
                        "同比增",
                        "16.09%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}